Clinical trial
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
NCT00432315 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00432315 |
|---|---|
| Title | Docetaxel in Non Small Cell Lung Cancer (NSCLC) |
| Official title | Multicenter Phase II Study Evaluating Docetaxel and CDDP as Induction Regimen Prior to Surgery or Radiochemotherapy With Docetaxel, Followed by Adjuvant Docetaxel Therapy in Chemonaive Patients With NSCLC Stage II, IIIa and IIIb |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Squamous Cell |
| Intervention type | Drug |
| Interventions | Docetaxel + CDDP, docetaxel + CDDP |
| Enrollment | 80 |
| Start date | May 1, 2001 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Feb 7, 2007 |
| Last update posted | Sep 14, 2010 |
| Countries | Austria |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: